within Pharmacolibrary.Drugs.V_Various.V03A_AllOtherTherapeuticProducts.V03AF09_Glucarpidase;

model Glucarpidase
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C(
    weight = 70,
    F = 1,
    Cl = 6.666666666666666e-07,
    adminDuration = 600,
    adminMass = 3900 / 1000000,
    adminCount = 1,
    Vd = 0.0035,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Glucarpidase</td></tr><tr><td>ATC code:</td><td>V03AF09</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>3900</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3.5</td><td>L</td></tr>
    <tr><td>clearance:</td><td>2.4</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Glucarpidase is an enzyme (carboxypeptidase G2) used to rapidly lower toxic plasma levels of methotrexate in patients with delayed methotrexate clearance due to renal impairment. It hydrolyzes methotrexate into inactive metabolites. The drug is approved for use in the United States for this specific indication.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in adult patients with impaired renal function who received glucarpidase 50 Units/kg intravenously as a single dose.</p><h4>References</h4><ol><li><p>Fukaya, Y, et al., &amp; Kawamoto, H (2023). Development of a population pharmacokinetics and pharmacodynamics model of glucarpidase rescue treatment after high-dose methotrexate therapy. <i>Frontiers in oncology</i> 13 1003633–None. DOI:<a href=\"https://doi.org/10.3389/fonc.2023.1003633\">10.3389/fonc.2023.1003633</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36793598/\">https://pubmed.ncbi.nlm.nih.gov/36793598</a></p></li><li><p>Taylor, ZL, et al., &amp; Ramsey, LB (2020). MTXPK.org: A Clinical Decision Support Tool Evaluating High-Dose Methotrexate Pharmacokinetics to Inform Post-Infusion Care and Use of Glucarpidase. <i>Clinical pharmacology and therapeutics</i> 108(3) 635–643. DOI:<a href=\"https://doi.org/10.1002/cpt.1957\">10.1002/cpt.1957</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32558929/\">https://pubmed.ncbi.nlm.nih.gov/32558929</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.V.V03AF09 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Glucarpidase;
